Release
📈 Stocks
Biocon Receives EU Approval for Pebrilzo, First EMA-Focused Biosimilar
(just now)
Biocon secures EU approval for its Pertuzumab biosimilar, Pebrilzo, marking the first such authorization under the EMA's new focused clinical pathway and…